Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results

Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the pu...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Frontiers in immunology Ročník 12; s. 657711
Hlavní autoři: Lombardi, Andrea, Bozzi, Giorgio, Ungaro, Riccardo, Villa, Simone, Castelli, Valeria, Mangioni, Davide, Muscatello, Antonio, Gori, Andrea, Bandera, Alessandra
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland Frontiers Media S.A 12.03.2021
Témata:
2019-nCoV Vaccine mRNA-1273
Animals
antibodies
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
BNT162 Vaccine
COVID-19
COVID-19 - blood
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 Vaccines - adverse effects
COVID-19 Vaccines - therapeutic use
CTL
Diffusion of Innovation
Host-Pathogen Interactions
Humans
Immunization
Immunogenicity, Vaccine
Immunology
mRNA Vaccines
neutralization test
RNA vaccine
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Treatment Outcome
Vaccines, Synthetic - adverse effects
Vaccines, Synthetic - therapeutic use
COVID-19
SARS-CoV-2
CTL
antibodies
RNA vaccine
neutralization test
ISSN:1664-3224, 1664-3224
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T H 1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Edited by: Gene S. Tan, J. Craig Venter Institute (La Jolla), United States
This article was submitted to Vaccines and Molecular Therapeutics, a section of the journal Frontiers in Immunology
Reviewed by: Sang-Moo Kang, Georgia State University, United States; Salvador Iborra, Universidad Complutense de Madrid, Spain
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2021.657711